Pucotenlimab and MRG002 for HER2-positive cancer of unknown primary
Part of Cancer clinical trials.
This trial tests a combination of two drugs—an immunotherapy (pucotenlimab) and a targeted drug (MRG002)—for people whose cancer started in an unknown location and has a specific protein called HER2. It is for those whose cancer has already been treated with at least one prior therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cancer of unknown primary that is HER2-positive (IHC 2+ or 3+).
- You have had at least one prior treatment (like chemo, targeted therapy, or immunotherapy) and your cancer got worse.
- You are able to provide a tumor sample for testing.
- You are 18 years or older and in generally good health (ECOG score 0 or 1).
- You do not have active infections, serious heart problems, or uncontrolled illnesses.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs for people with HER2-positive early breast cancer whose tumors did not respond well to the first round of standard targeted therapy plus chemo. The goal is to see if switching to trastuzumab-rezetecan plus pertuzumab or a different chemo combo (nab-paclitaxel, carboplatin, trastuzumab, and pyrotinib) can shrink the tumor before surgery.
This trial tests two drugs together: MRG003 (a targeted therapy that delivers chemo directly to EGFR-positive cancer cells) and pucotenlimab (an immunotherapy that helps your immune system attack the cancer). It is for people with a rare and aggressive thyroid cancer (ATC or PDTC) whose tumors have the EGFR protein and have grown despite previous treatment.
This trial tests a combination of two drugs, trastuzumab deruxtecan (SHR-A1811) and pertuzumab, given before surgery to shrink HER2-positive breast cancer. It is for women with stage II or III breast cancer who have not yet had treatment and are in good overall health.
This trial tests two experimental drugs, SI-B003 and BL-B01D1 plus SI-B003, for people with HER2-negative breast cancer that has spread or cannot be removed by surgery. It is for those who have tried standard treatments or cannot have them.
This trial tests a combination of two drugs (KN026 and HB1801) given after surgery to prevent breast cancer from coming back in people with HER2-positive breast cancer that had spread to lymph nodes. It aims to improve cure rates with a targeted approach.
This trial tests two different drug combos—one using an EGFR-targeted therapy alone, the other adding an immunotherapy—before standard chemoradiation for locally advanced head and neck cancer. The goal is to see which approach works better without prior treatment.
Hear when a new Cancer of Unknown Primary trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.